Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)
/in Hyperthermia, International Publications, Prostate Cancer /von 2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-200Potentiating prostate cancer immunotherapy with oncolytic viruses
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-250Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
/in Dendritic Cells, International Publications, Prostate Cancer /von 2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235Current status of clinical trials assessing oncolytic virus therapy for urological cancers
/in Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von 2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de